Effect of preimplantation genetic testing for aneuploidy on pregnancy outcomes of patients with recurrent miscarriage: a retrospective study Authors: Mingli Dong, Minyue Ma, Jialin Liu, Sha Mu, Yizhuo Yang, Yuan Gao Published: 2026 ABSTRACT BackgroundMiscarriage is a common complication of pregnancy, and it is defined as spontaneous pregnancy loss before the fetus reaches viability. However, there are no clear pathological factors identified as causes of recurrent miscarriage in some cases. Preimplantation genetic testing for aneuploidy (PGT-A) has been shown to have some advantages in the live birth rate in limited populations with a favorable prognosis. Hence, we investigated whether PGT-A improves pregnancy outcomes in patients with recurrent pregnancy loss.MethodsWe conducted a retrospective study including patients with a history of recurrent pregnancy loss from December 2021 to June 2022 receiving assisted reproduction therapy in the first medical center of the Chinese PLA General Hospital. The patients were divided into PGT-A and non-PGT-A groups, and we compared the pregnancy outcomes between the PGT-A and non-PGT-A groups.ResultsPGT-A significantly increased the clinical pregnancy rate per embryo transfer (ET) (58.7 vs. 32.3%, p = 0.023) and live birth rate per ET (50.0 vs. 25.8%, p = 0.034). However, there were no differences in biochemical pregnancy rates per ET (69.6 vs. 51.6%, P = 0.111), biochemical pregnancy loss rates (15.6 vs. 37.5%, p = 0.089), and miscarriage rate per clinical pregnancy (11.5 vs. 20.0%, p = 0.511) between the PGT-A and non-PGT-A groups.ConclusionsPGT-A was associated with significant improvements in clinical pregnancy and live birth rates in patients with recurrent pregnancy loss.Trial registrationThis study was registered at the Chinese Clinical Trial Registry (ChiCTR2200056991 http//www.chictr.org.cn/). Registration Date 20,220,225. Background Miscarriage is known as the most common complication of pregnancy; it is defined as spontaneous pregnancy loss before the fetus reaches viability, usually before 24 weeks of gestation [1, 2]. There are two types of miscarriage: sporadic and recurrent. However, in defining recurrent miscarriage, a consensus has not been reached regarding the number of pregnancies lost. The UK Royal College of Obstetricians and Gynecologists (RCOG) has defined recurrent miscarriage as the loss of three or more consecutive pregnancies [3]. According to the American Society for Reproductive Medicine (ASRM), recurrent miscarriage is defined as two or more consecutive pregnancy losses [4]. In China, most clinicians agree to define recurrent miscarriage as two or more losses. However, this may cause the inclusion of 1–5% of couples trying to conceive in this problem [5]. They believe that this makes it possible for patients to receive earlier clinical management and therapeutic interventions and avoid more pregnancy losses. Recurrent miscarriages haunt approximately 2% of couples trying to conceive [6]. Generally, genetic abnormalities, structural abnormalities, infection, endocrine disturbances, and immune dysfunction, among others, have been identified as factors associated with recurrent miscarriage; however, for many of these, the available evidence does not satisfy the Bradford-Hill criteria for causation, and their precise etiological roles remain to be fully established. It is frustrating that despite undergoing systematic physical examination, at least 50% of couples cannot identify clear pathological factors contributing to recurrent miscarriages [6, 7]. Therefore, reproductive clinicians are trying to explore more effective therapeutic methods. Since the first “test-tube baby Louise Brown " was born in 1978, many infertile couples have had their children with the help of reproductive technology. Over the past four decades, many new clinical technologies have emerged. Some examples of these are embryo cryopreservation discovered in 1983, embryo screening pioneered in 1989, the accomplishment of the first sperm microinjection in 1990, and the screening of embryos for chromosomes achieved in 1993. Presently, embryos can also be screened for monogenetic disorders to ensure that parents do not transmit virulence genes to the next generation. While embryonic aneuploidy was the most common cause of recurrent pregnancy loss (RPL), with a frequency of 41% [8], it was hoped that preimplantation genetic testing for aneuploidy (PGT-A) would help. PGT-A was originally used in advanced-age infertile females to prevent miscarriage caused by aneuploidy. With the development of scientific technologies, it has been revealed that PGT-A has some advantages in terms of the live birth rate in limited populations with a favorable prognosis [9]. Embryonic aneuploidy is one of the most well-characterized contributors to RPL. Chromosomally abnormal embryos account for approximately 41–60% of pregnancy losses, and the frequency of aneuploidy increases with advancing maternal age [10–12]. Aneuploid embryos are typically unable to sustain normal implantation and placentation, leading to either failure of implantation, biochemical pregnancy loss, or early clinical miscarriage. By identifying and excluding aneuploid embryos prior to transfer, PGT-A theoretically reduces the likelihood of transferring embryos with lethal chromosomal errors, thereby improving the probability of successful implantation and live birth. It is acknowledged that preimplantation genetic testing for structural rearrangements (PGT-SR) is more widely recommended for couples in whom one partner carries a known chromosomal structural rearrangement (e.g., balanced translocation), as such rearrangements can give rise to unbalanced chromosomal complements in embryos [13, 14]. However, in the present cohort, all patients had confirmed normal karyotypes, making PGT-SR inapplicable. PGT-A was therefore selected as the appropriate intervention to address de novo aneuploidy arising during gametogenesis or early embryonic development, which represents the predominant genetic mechanism of RPL in karyotypically normal couples. However, there have been few studies concerning whether PGT-A use in patients with RPL would help improve their live birth rate and prevent miscarriages. Whether PGT-A confers consistent benefit in patients with RPL remains a subject of active debate, with some studies demonstrating improved live birth rates while others report no significant advantage, particularly when embryo yield is limited or maternal age is not controlled [15, 16]. More clinical data are needed to confirm the effect of PGT-A in patients with recurrent miscarriages. Therefore, we conducted the present study to analyze related cases of RPL, compare the pregnancy outcomes of patients with and without PGT-A use, and explore the clinical application of PGT-A in patients with recurrent abortion. Unlike previous studies that included heterogeneous patient populations or lacked rigorous exclusion of confounding etiologies, the present study enrolled patients with unexplained RPL and confirmed normal karyotypes, ensuring a more uniform cohort. Furthermore, this study is among the first to report PGT-A outcomes in a Chinese RPL population under standardized clinical protocols, thereby contributing population-specific data to the global literature. In addition, the results of this pilot study were used to calculate the sample size for a prospective RCT, further supporting its methodological contribution. Methods Patient selection and grouping We retrospectively analyzed patients with a history of recurrent pregnancy loss who received assisted reproduction therapy in the first medical center of the PLA General Hospital from December 2021 to June 2022. We aimed to determine if PGT-A improves pregnancy outcomes in patients with recurrent pregnancy loss. The inclusion criteria were patients diagnosed with secondary infertility with recurrent miscarriage (two or more previous clinical pregnancy losses) and normal karyotype of the couples. The exclusion criteria were as follows: genital tract anatomical abnormalities such as septate uterus, single-horned uterus, reproductive tract infections, antiphospholipid antibody syndrome, and high-risk factors such as toxic chemicals in the living environment of the couples. Enrolled patients were separated into two groups according to whether they underwent PGT-A. The decision to undergo PGT-A was not randomly assigned but was determined by a combination of patient preference and financial considerations. In China, PGT-A is not covered by public health insurance, and the additional cost (approximately ¥15,000–20,000 RMB per cycle) represents a significant financial burden for many families. Patients who elected to undergo PGT-A did so voluntarily after detailed counseling by their treating physician regarding the potential benefits, limitations, invasive nature of trophectoderm biopsy, and associated costs. Patients who declined PGT-A either cited financial constraints or expressed a preference to proceed with morphology-based embryo selection. To minimize selection bias, we confirmed that baseline demographic and clinical characteristics—including age, BMI, number of prior miscarriages, ovarian reserve markers (AFC, basal FSH, LH, E2), and smoking status—did not differ significantly between the two groups (all p > 0.05), suggesting that the two cohorts were comparable at baseline despite the non-random allocation. All patients underwent systematic examination, including ultrasonography or hysterosalpingography, chromosome analysis, diagnostic tests for antiphospholipid syndrome, and blood tests for hypothyroidism. The study protocol was approved by the Research Ethics Committee of the PLA General Hospital (S2022-008-01), and they approved our request for a waiver of informed consent. This study was registered at the Chinese Clinical Trial Registry as ChiCTR2200056991 (http://www.chictr.org.cn/). Ovarian stimulation, oocyte retrieval, embryo culture, and trophectoderm biopsy All patients underwent controlled ovarian hyperstimulation (COH), transvaginal oocyte retrieval, and embryo transfer (ET) per standard cycle. The protocols selected were based on the patients’ conditions, including age, ovarian reserve, and physician’s preference. The protocols of COH included a long protocol of gonadotropin-releasing hormone (GnRH) agonist, a short protocol of GnRH agonist, or a GnRH antagonist protocol [17]. Physicians detected follicular maturation using transvaginal ultrasonography. When the dominant follicle reached a diameter of > 18 mm, 10,000 IU human chorionic gonadotropin (hCG) was used. Thirty-six hours after the ‘trigger,’ patients underwent transvaginal ultrasonography-assisted oocyte retrieval. After removing cumulus cells, oocytes at the MII stage were fertilized by intracytoplasmic sperm injection (ICSI). Then about 16–18 h later, the laboratory staff assessed the fertilization outcome based on the presence of two pronuclei, and all zygotes were cultured to the blastocyst stage. Next, D5 or D6 blastocysts were selected for trophoblast ectoderm biopsy. For blastocyst biopsy, five to eight trophectoderm cells herniating from the hole in the zona pellucida created by the laser on day 3 were biopsied from the expanding blastocysts using a rubbing dissection method. The biopsied cells were washed in phosphate buffer saline (PBS) and transferred to a polymerase chain reaction (PCR) tube containing 2–4 µL of sterile PBS. All biopsied embryos were cryopreserved via vitrification at the blastocyst stage. Preimplantation genetic testing for aneuploidy and embryo transfer Trophectoderm biopsy samples (three to five trophectoderm cells) from patients who had undergone PGT-A were subjected to whole-genome amplification (WGA). The Multiple Annealing and Looping Based Amplification Cycles (MALBAC) WGA protocol was used to amplify biopsied trophectoderm cells following the commercial kit protocol from Yikon Genomics (YK001B). Approximately 2–4 mg of DNA was generated by MALBAC for next-generation sequencing (NGS) analysis. We sequenced the amplified genome of each sample using the Illumina HIseq 2500 platform. The number of embryos to be transplanted was strictly in accordance with the Ministry of Health regulations. For patients without PGT-A, blastocysts were selected for transfer based on their morphological grade. For patients who had undergone PGT-A, blastocysts with better morphology and normal chromosome karyotype were selected for transfer, and only euploid blastocysts were transferred. Comparison and statistical analysis Biochemical pregnancy was diagnosed as a serum hCG level > 5 mIU/ml on the 10th day after ET, but without a gestational sac viewed during transvaginal ultrasonography. Clinical pregnancy was diagnosed as either the presence of a gestational sac and fetal cardiac activity ascertained using transvaginal ultrasonography on the 28th day after ET. Miscarriage was diagnosed as pregnancy loss after clinical pregnancy was confirmed. To minimize potential bias arising from repeated treatment cycles in the same individual, only the first embryo transfer attempt per patient was included in all outcome analyses. Patients who underwent more than one ET were not included in subsequent transfer analyses. The primary outcome was the live birth rate per ET. Secondary outcomes included the clinical pregnancy rate per ET, biochemical pregnancy rate per ET, biochemical pregnancy loss rate, and clinical miscarriage rate per clinical pregnancy. Differences in the measured data were compared using Student’s t-test. Statistical data are shown as rate (%) and compared using the χ2 test between groups. All analyses were performed using the statistical software SPSS, version 24.0, and statistical significance was set at p < 0.05. A sample size calculation was performed based on the primary outcome (live birth rate per ET) to inform the design of a future prospective RCT. Using a two-sided α of 0.05 and a power (1 − β) of 0.80, the required sample size was estimated using the formula for comparison of two independent proportions. The calculation was performed using PASS 15.0 software. Results This study enrolled a total of 92 patients with a history of recurrent pregnancy loss, including 48 patients who underwent PGT-A and 44 patients in the control group (non-PGT-A). No significant differences were observed in the baseline characteristics between the two groups. The mean age in the PGT-A group was 34.46 ± 4.03 years, compared to 34.34 ± 4.25 years in the non-PGT-A group (p = 0.892). The mean body mass index (BMI) in the PGT-A group was 22.34 ± 2.57, and in the non-PGT-A group, it was 22.92 ± 3.46 (p = 0.364). The mean number of miscarriages was 2.94 ± 1.23 in the PGT-A group and 2.75 ± 1.04 in the non-PGT-A group (p = 0.433) (Table 1). Additionally, no significant differences were found between the two groups regarding ovarian reserve and baseline hormone levels. The antral follicle count (AFC) in the PGT-A group was 12.64 ± 6.48, and in the non-PGT-A group, it was 11.93 ± 6.46 (p = 0.059). The basal follicle-stimulating hormone (FSH) level was 8.08 ± 3.22 mIU/mL in the PGT-A group and 8.04 ± 3.19 mIU/mL in the non-PGT-A group (p = 0.079). The basal luteinizing hormone (LH) level was 4.93 ± 3.61 mIU/mL in the PGT-A group and 4.85 ± 3.73 mIU/mL in the non-PGT-A group (p = 0.088). The basal estradiol (E2) level was 50.18 ± 47.62 pg/mL in the PGT-A group and 49.87 ± 48.63 pg/mL in the non-PGT-A group (p = 0.893) (Table 1). In the PGT-A group, a total of 679 oocytes were retrieved from 48 patients, with 255 cultured to blastocysts. After PGT-A analysis, 109 of 255 blastocysts (42.75%) were identified as euploid. Of the 48 patients, 38 had at least one euploid blastocyst available for transfer. Of these 38 patients, 30 received single embryo transfer (SET) and 8 received double embryo transfer (DET), resulting in a total of 46 euploid blastocysts transferred; DET was performed in patients aged > 35 years in accordance with Chinese Ministry of Health regulations. The remaining 10 patients did not proceed to ET due to the absence of euploid blastocysts following PGT-A analysis. In the non-PGT-A group, 283 oocytes were retrieved from 44 patients, and 193 blastocysts were cultured. Of the 44 enrolled patients, 31 proceeded to ET, with one morphologically selected blastocyst transferred per patient (31 blastocysts in 31 patients, all SET). Of the remaining 13 patients who did not undergo ET during the study period, 7 had inadequate blastocyst development, 4 had their cycles cancelled due to clinical reasons including endometrial insufficiency or ovarian hyperstimulation syndrome (OHSS), and 2 withdrew from the study due to personal reasons (Table 2). Table 1Baseline demographics of PGT-A and non-PGT-A patients with recurrent pregnancy lossPGT-AaNon-PGT-Ap-valueNumber of enrolled patients4844Mean age ± SD*34.46 ± 4.0334.34 ± 4.250.892Mean BMIb ± SD22.34 ± 2.5722.92 ± 3.460.364Mean number of miscarriages ± SD2.94 ± 1.232.75 ± 1.040.433Mean number of previous live births00-Smokers2/481/440.533AFC (Antral Follicle Count)12.64 ± 6.4811.93 ± 6.460.059Basal FSHc (mIU/mL)8.08 ± 3.228.04 ± 3.190.079Basal LHd (mIU/mL)4.93 ± 3.614.85 ± 3.730.088Basal E2e (pg/mL)50.18 ± 47.6249.87 ± 48.630.893a Preimplantation genetic testing for aneuploidy; b Body mass index; c Follicle-Stimulating Hormone; d Luteinizing Hormone; e Estradiol. * Standard deviation Table 1Baseline demographics of PGT-A and non-PGT-A patients with recurrent pregnancy lossPGT-AaNon-PGT-Ap-valueNumber of enrolled patients4844Mean age ± SD*34.46 ± 4.0334.34 ± 4.250.892Mean BMIb ± SD22.34 ± 2.5722.92 ± 3.460.364Mean number of miscarriages ± SD2.94 ± 1.232.75 ± 1.040.433Mean number of previous live births00-Smokers2/481/440.533AFC (Antral Follicle Count)12.64 ± 6.4811.93 ± 6.460.059Basal FSHc (mIU/mL)8.08 ± 3.228.04 ± 3.190.079Basal LHd (mIU/mL)4.93 ± 3.614.85 ± 3.730.088Basal E2e (pg/mL)50.18 ± 47.6249.87 ± 48.630.893a Preimplantation genetic testing for aneuploidy; b Body mass index; c Follicle-Stimulating Hormone; d Luteinizing Hormone; e Estradiol. * Standard deviation Baseline demographics of PGT-A and non-PGT-A patients with recurrent pregnancy loss a Preimplantation genetic testing for aneuploidy; b Body mass index; c Follicle-Stimulating Hormone; d Luteinizing Hormone; e Estradiol. * Standard deviation There was no statistically significant difference in the biochemical pregnancy rate per ET between the PGT-A and non-PGT-A groups (69.6 vs. 51.6%, p = 0.111). There was no statistically significant difference in biochemical pregnancy loss rates (15.6 vs. 37.5%, p = 0.089). In addition, there was no significant difference in the miscarriage rate per clinical pregnancy (11.5 vs. 20.0%, p = 0.511). However, PGT-A significantly increased the clinical pregnancy rate per ET (58.7% in the PGT-A group vs. 32.3% in the non-PGT-A group, p = 0.023), in the PGT-A and non-PGT-A groups. The live birth rate per ET was significantly higher in the PGT-A group than in the non-PGT-A group (50.0 vs. 25.8%, p = 0.034). Ectopic pregnancy rates were similar in both groups (p = 0.529). In addition, we compared the rate of total pregnancy loss per patient, which included both clinical miscarriage and biochemical pregnancy loss; however, there was no significant difference between the two groups (19.6 vs. 25.8%, p = 0.517). Based on the live birth rates observed in this pilot study (PGT-A: 50.0%; non-PGT-A: 25.8%), a sample size calculation for a future RCT indicated that a minimum of 67 patients per group (total n = 134) would be required to detect this difference with 80% power at a two-sided significance level of α = 0.05. Accounting for an estimated 15% dropout rate based on historical loss-to-follow-up rates reported in similar RPL studies, we recommend enrolling at least 79 patients per group (total n = 158) in a subsequent RCT. Table 2Comparison of embryological and clinical outcomes between PGT-A and non-PGT-A patients with recurrent pregnancy lossEmbryological OutcomesPGT-Aa (n = 48)Non-PGT-A (n = 44)p-valueTotal oocytes retrieved679283-Total blastocysts cultured255193-Euploid blastocysts / diagnosed blastocysts109/255 (42.75%)N/A-Patients proceeding to ET38/48 (79.2%)31/44 (70.5%)-SET / DET30 SET / 8 DET31 SET / 0 DET-Total embryo transfers (ET)46b31c-Biochemical pregnancies / ET32/46 (69.6%)16/31 (51.6%)0.111Biochemical pregnancy losses / biochemical pregnancies 5/32 (15.6%)6/16 (37.5%)0.089Clinical pregnancies / ET27/46 (58.7%)10/31 (32.3%)0.023Miscarriages / clinical pregnancies3/26 (11.5%)d2/10 (20.0%)0.511Ectopic pregnancies / clinical pregnancies1/26 (3.8%)d0/10 (0%)0.529Live births / ET23/46 (50.0%)8/31 (25.8%)0.034Total pregnancy loss / ET9/46 (19.6%)8/31 (25.8%)0.517a PGT-A: Preimplantation genetic testing for aneuploidy; b Of the 48 patients in the PGT-A group, 38 had at least one euploid blastocyst available for transfer. Of these 38 patients, 30 received single embryo transfer (SET) and 8 received double embryo transfer (DET), resulting in a total of 46 euploid blastocysts transferred. DET was performed in patients aged > 35 years in accordance with Chinese Ministry of Health regulations. The remaining 10 patients did not proceed to ET due to the absence of euploid blastocysts following PGT-A analysis; c Of the 44 patients in the non-PGT-A group, 31 proceeded to ET, with one morphologically selected blastocyst transferred per patient (31 blastocysts in 31 patients, all SET). Of the remaining 13 patients, 7 had inadequate blastocyst development, 4 had their cycles cancelled due to clinical reasons including endometrial insufficiency or ovarian hyperstimulation syndrome (OHSS), and 2 withdrew from the study due to personal reasons; d Of the 27 clinical pregnancies in the PGT-A group, this patient was confirmed to have achieved a live birth based on delivery records available in the hospital information system, though detailed obstetric follow-up data were unavailable and is therefore included in the live birth analysis. Subsequent miscarriage and ectopic pregnancy rates are thus reported based on the remaining 26 pregnancies Table 2Comparison of embryological and clinical outcomes between PGT-A and non-PGT-A patients with recurrent pregnancy lossEmbryological OutcomesPGT-Aa (n = 48)Non-PGT-A (n = 44)p-valueTotal oocytes retrieved679283-Total blastocysts cultured255193-Euploid blastocysts / diagnosed blastocysts109/255 (42.75%)N/A-Patients proceeding to ET38/48 (79.2%)31/44 (70.5%)-SET / DET30 SET / 8 DET31 SET / 0 DET-Total embryo transfers (ET)46b31c-Biochemical pregnancies / ET32/46 (69.6%)16/31 (51.6%)0.111Biochemical pregnancy losses / biochemical pregnancies 5/32 (15.6%)6/16 (37.5%)0.089Clinical pregnancies / ET27/46 (58.7%)10/31 (32.3%)0.023Miscarriages / clinical pregnancies3/26 (11.5%)d2/10 (20.0%)0.511Ectopic pregnancies / clinical pregnancies1/26 (3.8%)d0/10 (0%)0.529Live births / ET23/46 (50.0%)8/31 (25.8%)0.034Total pregnancy loss / ET9/46 (19.6%)8/31 (25.8%)0.517a PGT-A: Preimplantation genetic testing for aneuploidy; b Of the 48 patients in the PGT-A group, 38 had at least one euploid blastocyst available for transfer. Of these 38 patients, 30 received single embryo transfer (SET) and 8 received double embryo transfer (DET), resulting in a total of 46 euploid blastocysts transferred. DET was performed in patients aged > 35 years in accordance with Chinese Ministry of Health regulations. The remaining 10 patients did not proceed to ET due to the absence of euploid blastocysts following PGT-A analysis; c Of the 44 patients in the non-PGT-A group, 31 proceeded to ET, with one morphologically selected blastocyst transferred per patient (31 blastocysts in 31 patients, all SET). Of the remaining 13 patients, 7 had inadequate blastocyst development, 4 had their cycles cancelled due to clinical reasons including endometrial insufficiency or ovarian hyperstimulation syndrome (OHSS), and 2 withdrew from the study due to personal reasons; d Of the 27 clinical pregnancies in the PGT-A group, this patient was confirmed to have achieved a live birth based on delivery records available in the hospital information system, though detailed obstetric follow-up data were unavailable and is therefore included in the live birth analysis. Subsequent miscarriage and ectopic pregnancy rates are thus reported based on the remaining 26 pregnancies Comparison of embryological and clinical outcomes between PGT-A and non-PGT-A patients with recurrent pregnancy loss a PGT-A: Preimplantation genetic testing for aneuploidy; b Of the 48 patients in the PGT-A group, 38 had at least one euploid blastocyst available for transfer. Of these 38 patients, 30 received single embryo transfer (SET) and 8 received double embryo transfer (DET), resulting in a total of 46 euploid blastocysts transferred. DET was performed in patients aged > 35 years in accordance with Chinese Ministry of Health regulations. The remaining 10 patients did not proceed to ET due to the absence of euploid blastocysts following PGT-A analysis; c Of the 44 patients in the non-PGT-A group, 31 proceeded to ET, with one morphologically selected blastocyst transferred per patient (31 blastocysts in 31 patients, all SET). Of the remaining 13 patients, 7 had inadequate blastocyst development, 4 had their cycles cancelled due to clinical reasons including endometrial insufficiency or ovarian hyperstimulation syndrome (OHSS), and 2 withdrew from the study due to personal reasons; d Of the 27 clinical pregnancies in the PGT-A group, this patient was confirmed to have achieved a live birth based on delivery records available in the hospital information system, though detailed obstetric follow-up data were unavailable and is therefore included in the live birth analysis. Subsequent miscarriage and ectopic pregnancy rates are thus reported based on the remaining 26 pregnancies Discussion ART is the main therapy for infertile couples, and PGT is the main method to help infertile couples with a poor pregnancy prognosis. Aneuploidy (a change in normal chromosome copy number) has been reported as the major genetic cause of IVF failure in infertile patients [18]. More than 50% of embryos from patients of advanced maternal age (> 35 years) that experienced multiple implantation failures or RPLs were aneuploid [19]. In previous clinical practice, patients diagnosed with a high risk of aneuploidy underwent PGT-A using either a 24-chromosome array or real-time PCR technologies [20, 21] to identify euploid embryos for transplantation. NGS has more recently emerged as a mainstream technology for identifying chromosomal abnormalities in oocytes [22] and embryos [23–25] at a much higher chromosomal resolution than arrays. Approximately 77% of 386 IVF units in 70 countries currently perform preimplantation genetic screening routinely in clinical practice for various indications [26]. However, embryo biopsy is an invasive procedure, and according to the recommendation of the ASRM, there is insufficient evidence to support the general use of PGT-A for couples with infertility. More evidence-based medical studies are needed to verify which populations are more likely to benefit from this test. Whether PGT-A can improve clinical outcomes in patients with recurrent miscarriages is still widely debated. Therefore, we conducted a retrospective study of patients with recurrent abortions at our center. In the present study, we demonstrated that the use of PGT-A increased the clinical pregnancy and live birth rates in patients with RPL. However, we failed to show that PGT-A reduced the rate of biochemical pregnancy loss and clinical miscarriages. These findings are consistent with the few studies that have evaluated the effects of PGT-A, specifically in patients with RPL. In 2016, Murugappan et al. [27] conducted a retrospective cohort study. They reported no difference in pregnancy outcomes in women with RPL, whether the patient underwent PGT-A or only expectant management without IVF. Nevertheless, Rienzi et al. [28] published a critical review to cite the bias of the study methodology for the lack of maternal age control. Moreover, the study cautioned against the use of PGT-A in couples with low embryo yield or quality. Rienzi et al. believed that PGT-A should be applied to women with poor embryo quality; thus, the conclusions of the study by Murugappan were not compelling enough. In 2019, a multicenter pilot study demonstrated that PGT-A improved the live birth rate per ET procedure [29]. More recently, Bhatt et al. conducted the first large retrospective database study and found a significant increase in clinical pregnancy and live birth rates with PGT-A use in women with RPL. Moreover, the benefit of PGT-A was more pronounced in patients of advanced maternal age [30]. Our data further prove that PGT-A use would improve the pregnancy outcomes of couples with RPL. In addition, contrary to our expectations, we failed to demonstrate that the use of PGT-A decreased biochemical pregnancy losses and clinical miscarriages due to the lack of a statistically significant difference. Although, their rates were lower in the PGT-A group than in the non-PGT-A group. We considered the following as possible reasons for these results. On the one hand, abnormalities in endometrial receptivity may facilitate aneuploid embryo implantation. Teklenburg et al. indicated that RPL is associated with impaired differentiation of endometrial stromal cells into specialized decidual cells [31]. However, the existence of chimeric embryos remains a major challenge to the accuracy of PGT-A results. Popovic et al. showed that the probability of consistent trophoblast ectoderm cells and inner cell mass biopsy results was 62% [32]. Moreover, Maxwell et al. used trophoblast cells from different parts for repeated biopsies and found that the consistency rate between the two results was only 48.3% [33]. It was also proven that not all chimeric embryos should be discarded for their potential to implant and finally result in a live birth. Nearly 100 live births of chimeric embryos had been reported worldwide as of 2018 [34]. Embryo biopsy is an otherwise invasive procedure, although it is relatively safe, and no studies have reported that there are abnormalities or defects in the growth of children born with the aid of PGT. We still do not know the influence of intense mechanical pulling and laser cutting during biopsy in the process of embryo development and implantation. For these reasons, PGT-A failed to reduce miscarriage rates in patients with RPL. It is hoped that embryo biopsy will be gradually replaced by a noninvasive and more accurate preimplantation chromosome screening technology. One limitation of this study is that the sample size was relatively small and the study was retrospective rather than randomized. Although the PGT-A and non-PGT-A groups were comparable in measured baseline demographic and clinical characteristics, the decision to undergo PGT-A was influenced by patient preference and financial considerations because PGT-A was self-funded and not covered by public health insurance. This may have introduced selection bias and residual confounding, as patients who chose PGT-A may have differed from those who declined PGT-A in terms of socioeconomic status, health-seeking behavior, treatment expectations, risk tolerance, and willingness to pursue additional interventions. These unmeasured differences may have influenced treatment decisions, adherence to follow-up, and reproductive outcomes. Therefore, the observed improvement in clinical pregnancy and live birth rates should be interpreted as an association rather than definitive evidence of causality. Due to the limitations of archived medical records, we could only identify complete data for patients treated between December 2021 and June 2022. Furthermore, the present pilot study was used to calculate the sample size for a subsequent prospective randomized controlled trial. Future adequately powered randomized controlled trials are needed to minimize selection bias and to further confirm the effect of PGT-A on pregnancy outcomes in patients with recurrent pregnancy loss. Conclusions In conclusion, our retrospective study demonstrates that PGT-A significantly enhances clinical pregnancy and live birth rates per ET in patients with RPL. These findings suggest that PGT-A may serve as a valuable tool in improving reproductive outcomes for this specific patient population. However, the lack of significant differences in biochemical pregnancy rates, biochemical pregnancy loss rates, and miscarriage rates per clinical pregnancy between the PGT-A and non-PGT-A groups indicates that further research is warranted to fully elucidate the broader implications of PGT-A in RPL management. Future prospective, randomized controlled trials with larger sample sizes are necessary to validate these findings and to explore the potential benefits of PGT-A in diverse patient cohorts.